Background: Precursor B-cell acute lymphocytic leukemia (ALL) with surface immunoglobulin light chain expression is a rare disease entity. The differential diagnosis is difficult but critical for disease management. Aims: We report 2 cases (1 adult and 1 infant) of precursor B-cell ALL who presented at diagnosis with surface immunoglobulin light chain expression revealed by flow cytometric immunophenotyping and discuss its clinical significance. Case Report: The 2 patients presented with nonspecific symptoms such as fever, pallor, fatigue or lymphadenopathy. Flow cytometric immunophenotyping showed that both patients expressed CD34/CD19/CD10/CD22/CD9/HLA-DR/CD38/CD123/CD13 (partial) and had unexpected single λ light chain expression. Cytogenetic analysis revealed t(9;22)(q34;q11) in the adult patient and normal karyotype in the infant. Both cases were diagnosed and managed as precursor B-ALL, and the patients showed good response to treatment regimens. Conclusion: We describe 2 cases of precursor B-ALL with unexpected surface light chain expression. The exceedingly rare immunophenotypes have diagnostic implication for immunophenotyping of this malignancy. Treatment regimens for precursor B-cell ALL are suitable for such cases.

Keywords:
Precursor B cell, Acute lymphoblastic leukemia, Immunophenotype, Surface immunoglobulin light chain
1.
Jabbour EJ, Faderl S, Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005;80:1517-1527.
2.
Paolini S, Gazzola A, Sabattini E, Bacci F, Pileri S, Piccaluga PP: Pathobiology of acute lymphoblastic leukemia. Semin Diagn Pathol 2011;28:124-134.
3.
Hsi ED: The leukemias of mature lymphocytes. Hematol Oncol Clin North Am 2009;23:843-871.
4.
de Tute RM: Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies. Histopathology 2011;58:90-105.
5.
Behm FG, Head DR, Pui C-H, Rivera GR, Ribeiro RC, Raimondi SC: B-precursor ALL with unexpected expression of surface immunoglobulin (sIg) mu and lambda (abstract). Lab Invest 1995;72:106A.
6.
Michiels JJ, Adriaansen HJ, Hagemeijer A, Hooijkaas H, van Dongen JJ, Abels J: TdT positive B-cell acute lymphoblastic leukemia (B-ALL) without Burkitt characteristics. Br J Haematol 1988;68:423-426.
7.
Vasef MA, Brynes RK, Murata-Collins JL, Arber DA, Medeiros LJ: Surface immunoglobulin light chain-positive acute lymphoblastic leukemia of FAB L1 or L2 type: a report of 6 cases in adults. Am J Clin Pathol 1998;110:143-149.
8.
Kansal R, Deeb G, Barcos M, Wetzler M, Brecher ML, Block AW, Stewart CC: Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction: a report of 15 patients. Am J Clin Pathol 2004;121:512-525.
9.
Li S, Lew G: Is B-lineage acute lymphoblastic leukemia with a mature phenotype and l1 morphology a precursor B-lymphoblastic leukemia/lymphoma or Burkitt leukemia/lymphoma? Arch Pathol Lab Med 2003;127:1340-1344.
10.
Chan NP, Ma ES, Wan TS, Chan LC: The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res 2003;27:231-234.
11.
Frater JL, Batanian JR, O'Connor DM, Grosso LE: Lymphoblastic leukemia with mature B-cell phenotype in infancy. J Pediatr Hematol Oncol 2004;26:672-677.
12.
Hammami A, Chan WC, Michels SD, Nassar VH: Mature B-cell acute leukemia: a clinical, morphological, immunological, and cytogenetic study of nine cases. Hematol Pathol 1991;5:109-118.
13.
Ohtsuki T, Ogawa Y, Izumi T, Hatake K, Miura Y: Two cases of mature B-cell acute lymphocytic leukemia with normal karyotype in adults. Acta Haematol 1996;96:258-261.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.